In recent years, menopause has transitioned from a whispered-about taboo to a loud, ubiquitous, and highly profitable cultural phenomenon. While increased visibility for women’s health is generally welcomed, experts are raising alarms that the pendulum has swung toward a dangerous over-medicalization. What was once a natural life stage is being reframed as a "medical emergency," fueling a multi-billion dollar industry that critics have dubbed the "hot flush gold rush."
Sarah White, Chief Executive Officer of Jean Hailes for Women’s Health, has observed a troubling trend at the organization’s health clinics: a surge of younger women—some in their early 30s—attributing various physical and emotional symptoms to perimenopause. While perimenopause can occur early, it typically begins in the mid-40s. White is concerned that the immediate impulse to blame hormones is obscuring other critical health issues and life stressors.
"Let’s sort out that there’s nothing else going on here," White says. Her warning highlights a broader shift where menopause has become the "catch-all" diagnosis for midlife discomfort, leading to a surge in prescriptions for antidepressants and the marketing of questionable "menopause-branded" lifestyle products.
The Chronology of a Narrative Shift: From Silence to Meno-Washing
For decades, menopause was a private matter, often ignored by medical research and dismissed by society. This "data gap" created a vacuum of information that left many women feeling abandoned. However, the last decade has seen a rapid commercialization of this void.
The Rise of ‘Meno-washing’
As menopause became a trending topic on social media, commercial entities recognized a lucrative opportunity. Middle-aged women often possess more disposable income than younger demographics, making them an ideal target for "meno-washing"—the practice of branding everyday products with a menopause label to justify higher price points.
White, who previously served as the director of the Australian tobacco control program, Quit, notes a striking similarity between the tactics of big tobacco and the current menopause industry. "I could just see these companies who were trying to hijack a narrative online," she explains. This narrative portrays menopause as a period of inevitable deterioration that requires intervention.
Today, the market is flooded with "menopause chocolate," "menopause tea," and even "menopause socks." These products often lack any scientific link to symptom relief but are marketed through a lens of "empowerment" or "care," suggesting that a woman’s worth and productivity depend on her ability to "fix" her transitioning body.
The Algorithm of Anxiety
Social media has played a pivotal role in this shift. Algorithms tend to amplify high-emotion content, meaning the most harrowing accounts of menopause are the ones most likely to go viral. Martha Hickey, Professor of Obstetrics and Gynaecology at the University of Melbourne, points out that a simple Google image search for "menopause" yields a sea of women fanning themselves or appearing on the verge of collapse.
"We don’t often see positive images," Hickey says. This constant exposure to negative tropes creates a "catastrophic" expectation of the transition, which research suggests can actually worsen the physical experience of symptoms.
Supporting Data: The Cost of Over-Medicalization
The medicalization of menopause is not merely a marketing issue; it has profound clinical implications. When menopause is treated as a disease rather than a transition, the primary response is often pharmaceutical.
The Antidepressant Surge
While Hormone Replacement Therapy (HRT) is the standard for treating vasomotor symptoms (hot flushes and night sweats), psychiatric drugs are being prescribed at alarming rates for the emotional distress associated with midlife. In the United States, women are approximately 2.5 times more likely to use antidepressants than men, with usage peaking in the 40s and 50s.
Furthermore, research indicates that women over 45 are nearly twice as likely to be diagnosed with anxiety disorders and 1.5 times as likely to be diagnosed with depressive disorders compared to men. This leads to high rates of SSRI (selective serotonin reuptake inhibitor) and SNRI (serotonin-norepinephrine reuptake inhibitor) prescriptions. For women in this age bracket, these drugs carry specific risks, including an increased likelihood of bone fractures and cardiovascular events.
The Symptom Inflation
One of the most significant drivers of the menopause industry is the expansion of what constitutes a "symptom." Professor Hickey notes that while nearly 200 symptoms are currently ascribed to menopause in popular discourse, scientific research has only clearly linked two—vaginal dryness and vasomotor symptoms—directly to the hormonal changes of the transition.
By attributing everything from brain fog to joint pain exclusively to menopause, the medical community and commercial brands may be ignoring the "midlife collision"—the intense intersection of caring for elderly parents, raising children, facing workplace ageism, and navigating financial pressures.
Official Responses and the Call for Regulation
The rise in "menopause-friendly" branding has caught the attention of regulatory bodies. Sarah White, as part of the Women’s Health Products Working Group for Australia’s Therapeutic Goods Administration (TGA), is advocating for a more rigorous look at how these products are marketed.
The Productivity Trap
A particularly controversial development is the rise of "menopause-friendly" workplace accreditations. While intended to support employees, White argues that the training packages sold to businesses often rely on "disgraceful" data suggesting that women hit a "productivity cliff" at menopause.
"To sell the training package, [companies] have to convince the business that they need it," White explains. This reinforces a bias that middle-aged women are liabilities in the workplace, despite data showing they are a highly productive and essential subpopulation.
The Need for Unbiased Education
Experts are calling for a decoupling of education and industry. Currently, many "educational" events and resources are sponsored by pharmaceutical companies or brands with a vested interest in pathologizing the transition.
Hickey and White emphasize that women need "consistent" information from trusted, non-commercial sources. The goal, as White puts it, is to ensure women are "prepared, but not scared."
Implications: Changing the Cultural Architecture
The experience of menopause is not universal; it is deeply influenced by the culture in which a woman lives. This suggests that the "symptoms" we treat as biological imperatives may, in fact, be partially shaped by social structures.
Cultural Variations
In Western cultures, where a woman’s value is often tied to youth and reproductive capacity, menopause is frequently viewed as a loss of status. However, in other cultures, the transition is viewed with reverence:
- China: The phase is often called a "second spring," a time of rebirth. Research shows Chinese women report lower distress and fewer symptoms than their Western counterparts.
- Indigenous Cultures: Menopause is seen as a natural transition into the role of a respected elder. Vasomotor symptoms are reported to be significantly less common in these communities.
- Migration Studies: A landmark 2009 study found that Indian women who migrated to the UK reported higher rates of hot flushes than those who remained in India, suggesting that the medicalized environment of the UK influenced their physical experience of the transition.
The Role of Cognitive Behavioral Therapy (CBT)
If thoughts and expectations can worsen symptoms—a process known as catastrophizing—then changing those thoughts can offer relief. White suggests that CBT can be a powerful tool, not to "think away" the pain, but to manage it. By restructuring how a woman thinks about a hot flush, the symptom becomes more manageable and less distressing.
A Structural Solution
Ultimately, the medicalization of menopause is a "band-aid" for deeper societal issues. Taking a pill or buying "menopause tea" does not alleviate the burden of the "sandwich generation" or the sting of workplace ageism.
"It’s the structural things we need to change, not just taking a pill that’s suddenly going to make everything all right," White concludes.
The path forward requires a nuanced approach: acknowledging the genuine discomfort some women face while resisting the urge to turn a natural life stage into a commercialized disease. Like pregnancy, menopause is a normal biological event; it usually goes fine, and when it doesn’t, medical help should be available—but the help should not be the default for every woman. Changing the narrative from one of "deterioration" to one of "transition" may be the most effective "treatment" of all.
